ASCO - CAP Collaboration Richard L. Schilsky, MD ASCO Chief Medical - PowerPoint PPT Presentation

ASCO - CAP Collaboration Richard L. Schilsky, MD ASCO Chief Medical Officer NCCS Cancer Policy Roundtable March 31, 2015

Rationale for Collaboration • Pathology-oncology partnership critical in cancer diagnosis and precision medicine • Oncologists and pathologists increasingly working in clinical treatment teams • Enhance and improve dissemination of treatment recommendations, education, and policy work

Guideline Collaborations In Development • Molecular Markers for the Evaluation of Colorectal Cancer • HER2 Testing in Gastric Cancer Published • Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer (original guideline in 2007 and 2013 update) • Recommendations for Immunohistochemical Testing of Estrogen/Progesterone Receptors in Breast Cancer

Molecular Oncology Tumor Boards • Crowd-sourced and discussion-based format • Each case moderated by a medical oncologist and pathologist • Average of 24 comments per discussion thread • 2015 Topics o January: Colorectal (KRAS) o February: Lung (ROS1) o March: Breast (PIK3CA) o April: CLL (TP53); will launch 4/22

Molecular TB Page Views

ASCO-CAP Pathology Workshop July 10, 2015 • Lack of pathology capacity in limited resource settings a key contributor to late diagnosis and poor patient outcomes • Workshop to convene: – Oncologists and pathologists from four pilot countries: Honduras, Vietnam, Uganda and Haiti – ASCO and CAP members with experience in these settings • Objectives: – Identify common pathology challenges and needs – Assess models for improving pathology capacity in these settings – Determine what models can be applied to pilot countries – Determine how ASCO and CAP can support these efforts 6

March 2014 Genomics Roundtable • Goal: Ensure that cancer patients & specialists have access to high quality genomic testing & easily understandable test results relevant to clinical decision-making • Conveners – ASCO, CAP, & AMP • Participants: – Patient representatives – Diagnostic companies & commercial labs – Academic clinicians & investigators

Next Steps – Consensus Standards • Reporting – Sequence variants – Report components • Specimens – Acquisition – Storage • Working Groups Forming • Timelines in Development

Policy Initiatives • Regulation of Lab-Developed Tests – FDA regulation needed to ensure analytic & clinical validity – Oncologists rely on high-quality tests for determining appropriate treatment = high-risk test • Companion Diagnostics Workshop – CAP involved on planning committee & panels – Goal: Engage stakeholders to discuss ways to address situations with multiple drugs & tests in the same class • Cancer Leadership Council – Monthly discussions to discuss key policy & advocacy activities

Other Activities • Cancer.Net  “ Spotlight On” Pathologists blog feature  Pathologist-Generated Content and Images from MyBiopsy.org  “How to Read Your Pathology Report” (future content sharing) • Health Information Technology  Relationship between CAP Pathology Electronic Reporting (PERT) Committee and ASCO HIT Group  CancerLinQ